Management of Advanced Ovarian, Fallopian Tube, and Primary Peritoneal Cancers

Treatment approaches for advanced ovarian cancer should consider several factors. Among the most important are platinum sensitivity, status of BRCA and homologous recombination deficiency (HRD), changing indications PARP inhibitors in recurrent disease maintenance. have demonstrated clear benefit patients with mutated tumors, especially first-line setting, HRD testing can guide their use without mutations. A new antibody–drug conjugate, mirvetuximab soravtansine, has been approved a subset platinum-resistant disease. Newly diagnosed advanced-stage ovarian, fallopian tube, or primary peritoneal cancers always be evaluated by gynecologic oncologist if possible.